Milestone Pharmaceuticals Stock Performance
| MIST Stock | USD 1.76 0.04 2.33% |
The company secures a Beta (Market Risk) of 1.04, which conveys a somewhat significant risk relative to the market. Milestone Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Milestone Pharmaceuticals is expected to follow. Milestone Pharmaceuticals right now secures a risk of 4.64%. Please verify Milestone Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Milestone Pharmaceuticals will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Milestone Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Milestone Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1 | Acquisition by Lorenz Muller of 66666 shares of Milestone Pharmaceuticals at 1.5 subject to Rule 16b-3 | 11/21/2025 |
2 | Jefferies Lifts Milestone Pharmaceuticals Price Targets on Product Sales Prospects | 11/25/2025 |
3 | Disposition of 25000 shares by Lorenz Muller of Milestone Pharmaceuticals subject to Rule 16b-3 | 12/09/2025 |
4 | Milestone Pharmaceuticals Cut to Sell at Wall Street Zen | 12/16/2025 |
5 | Disposition of 500 shares by Oliveto Joseph of Milestone Pharmaceuticals at 2.25 subject to Rule 16b-3 | 01/07/2026 |
6 | Disposition of 43000 shares by Oliveto Joseph of Milestone Pharmaceuticals at 2.25 subject to Rule 16b-3 | 01/08/2026 |
7 | Milestone Pharmaceuticals Inc. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat | 01/14/2026 |
8 | Aug Mood Should I invest in Milestone Pharmaceuticals Inc before earnings - CPI Data Daily Profit Focused Screening - baoquankhu1.vn | 01/20/2026 |
9 | Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paro... | 01/26/2026 |
10 | Milestone Pharmaceuticals Upgraded at Zacks Research | 01/28/2026 |
11 | Acquisition by Oliveto Joseph of 453000 shares of Milestone Pharmaceuticals subject to Rule 16b-3 | 02/02/2026 |
12 | Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/03/2026 |
| Begin Period Cash Flow | 13.8 M | |
| Total Cashflows From Investing Activities | 8.3 M |
Milestone | Build AI portfolio with Milestone Stock |
Milestone Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 185.00 in Milestone Pharmaceuticals on November 10, 2025 and sell it today you would lose (9.00) from holding Milestone Pharmaceuticals or give up 4.86% of portfolio value over 90 days. Milestone Pharmaceuticals is currently generating 0.0273% in daily expected returns and assumes 4.6431% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Milestone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Milestone Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Milestone Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.76 | 90 days | 1.76 | about 90.32 |
Based on a normal probability distribution, the odds of Milestone Pharmaceuticals to move above the current price in 90 days from now is about 90.32 (This Milestone Pharmaceuticals probability density function shows the probability of Milestone Stock to fall within a particular range of prices over 90 days) .
Milestone Pharmaceuticals Price Density |
| Price |
Predictive Modules for Milestone Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Milestone Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Milestone Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Milestone Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Milestone Pharmaceuticals is not an exception. The market had few large corrections towards the Milestone Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Milestone Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Milestone Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.06 | |
β | Beta against Dow Jones | 1.04 | |
σ | Overall volatility | 0.30 | |
Ir | Information ratio | -0.01 |
Milestone Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Milestone Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Milestone Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals had very high historical volatility over the last 90 days | |
| Milestone Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (28.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Milestone Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Milestone Stock often depends not only on the future outlook of the current and potential Milestone Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Milestone Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.2 M | |
| Cash And Short Term Investments | 69.7 M |
Milestone Pharmaceuticals Fundamentals Growth
Milestone Stock prices reflect investors' perceptions of the future prospects and financial health of Milestone Pharmaceuticals, and Milestone Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Milestone Stock performance.
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 124.52 M | ||||
| Shares Outstanding | 85.17 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 7.31 X | ||||
| Price To Sales | 77.32 X | ||||
| EBITDA | (37.83 M) | ||||
| Net Income | (41.52 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 54.8 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.85 M) | ||||
| Earnings Per Share | (0.79) X | ||||
| Market Capitalization | 149.9 M | ||||
| Total Asset | 75.5 M | ||||
| Retained Earnings | (367.55 M) | ||||
| Working Capital | 65.8 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
About Milestone Pharmaceuticals Performance
Assessing Milestone Pharmaceuticals' fundamental ratios provides investors with valuable insights into Milestone Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Milestone Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.72) | (0.75) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (3.63) | (3.45) |
Things to note about Milestone Pharmaceuticals performance evaluation
Checking the ongoing alerts about Milestone Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Milestone Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals had very high historical volatility over the last 90 days | |
| Milestone Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (28.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing Milestone Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Milestone Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Milestone Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Milestone Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Milestone Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Milestone Pharmaceuticals' stock. These opinions can provide insight into Milestone Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.